All In Biotech

Drug Trial Radar · NCT02057172

Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

A Phase II, 12-week, Double-blind, Randomised, Parallel Group, Multi-centre, International Trial to Assess the Effect on Glycaemic Control of Five Doses of HM11260C Versus Placebo or Open-label Liraglutide in Subjects With Type 2 Diabetes

Last checked: Nov 19, 2026Latest source record: Aug 9, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 254 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

254

Actual

Start

Jan 2014

Primary completion

Oct 2014

Study completion Dec 2014

Sponsor

Sponsor type
Industry
First posted
Feb 6, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the optimal dose or doses of HM11260C, when administered once a week under the skin, to improve the control of blood sugar levels in patients with early-stage type 2 diabetes mellitus (T2DM).

Conditions

  • Type 2 Diabetes

Interventions

  • HM11260CDrug

    HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)

  • liraglutideDrug

    Liraglutide is a GLP-1 agonist.

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in baseline in glycosylated haemoglobin (HbA1c) at 12 weeksTime frame: Up to 127 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hanmi pharmaceutical

    CA, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.